Septest Limited

Based in the UK, Septest Limited, operates as a provider of infection and inflammation diagnostic testing solutions for healthcare providers. Based in Hertford, the UK and founded in 2022, Septest Limited offers diagnostic solutions aimed at early detection of infections and inflammatory responses. The company raised GBP 1. 1 mn in Seed funding from investors including FundMyPitch, Keiretsu Forum, and Oxford Technology Management.

Recently, Septest Limited also secured an undisclosed amount of grant funding from the National Institute for Health Research. Septest specializes in developing innovative diagnostic solutions aimed at early detection of infections and inflammatory responses, primarily focusing on sepsis. Their flagship product, TRISEP, is a multi-marker test designed for pre-hospital and community triage settings, offering rapid results that enable healthcare professionals to make timely and informed treatment decisions. The test leverages advanced diagnostic technology to simplify the detection process of various infection types while ensuring ease of use in diverse healthcare environments, including general practice clinics and community health settings.

Serving a broad clientele that includes healthcare providers, pharmacists, and clinicians, Septest’s solutions are primarily tailored for markets needing point-of-need diagnostics, especially in low- and middle-income countries (LMICs) where access to rapid testing is critical. The revenue structure of Septest is based on direct sales of its diagnostic products, particularly the TRISEP test, to healthcare providers and institutions. The company operates on a B2B model, collaborating with medical facilities and community health providers interested in integrating their diagnostic solutions. Each transaction focuses on providing comprehensive diagnostic tools that enable healthcare professionals to quickly assess infections and inflammatory responses, a critical factor in infection management.

Septest’s partnerships with investors, such as Oxford Technology, further support its growth trajectory and enhance its capability to reach broader markets and healthcare initiatives. The company plans to utilize the recent grant funding to enhance its diagnostic capabilities and expand its market reach. Current initiatives include further development of the TRISEP test and exploring additional partnerships to improve access to rapid testing solutions.